GlaxoSmithKline (GSK) has agreed to a $105 million settlement with 44 US states and the District of Columbia over allegations it mispromoted three drugs.
The drugs are asthma medication Advair and anti-depressants Paxil and Wellbutrin.
The pharmaceutical giant did not admit any wrongdoing, and said the charges came from past issues.
As part of the settlement, GSK must extend its Patient First Program until 2019, which prohibits financial incentives to its sales people, and it is prohibited from paying doctors to speak about GSK’s products or attend conferences.
“This settlement requires GSK to pay a significant penalty and imposes strong new rules designed to prevent future misrepresentations of GSK products,” said California attorney general Kamala Harris in a statement.
GSK insists that many of these practices are already in place.